论文部分内容阅读
目的:探讨早期强化他汀治疗对急性冠脉综合征(ACS)患者炎症因子和预后的影响。方法:70例ACS患者随机分为常规他汀治疗组(A组)和强化他汀治疗组(B组),分别使用10 mg和40 mg阿托伐他汀进行治疗,检测治疗前和治疗1周时高敏C反应蛋白(hs-CRP)、血清淀粉样蛋白A(SAA)、基质金属蛋白酶9(MMP-9)、纤维蛋白原(Fib)和血脂水平,随访两组60天心血管事件和不良反应。结果:两组治疗前后血脂水平无显著性变化(P>0.05);A组hs-CRP、SAA、MMP-9水平有显著性下降(P<0.05),B组4种炎症因子均有显著性下降(P<0.05),且比A组下降得更低(P<0.05);B组总心血管事件发生率较A组低(P<0.05),两组均未发现明显不良反应。结论:早期强化他汀治疗能够降低炎症因子水平,减少心血管事件,具有很好的疗效和安全性。
Objective: To investigate the effect of early intensive statin therapy on inflammatory factors and prognosis in patients with acute coronary syndrome (ACS). Methods: Seventy patients with ACS were randomly divided into routine statin group (group A) and intensive statin group (group B). The patients were treated with atorvastatin 10 mg and 40 mg, respectively. Before and 1 week after treatment, C reactive protein (hs-CRP), serum amyloid A (SAA), matrix metalloproteinase 9 (MMP-9), fibrinogen (Fib) and blood lipids were measured. The two groups were followed up for 60 days of cardiovascular events and adverse reactions. Results: There was no significant difference in serum lipids between the two groups before and after treatment (P> 0.05). The levels of hs-CRP, SAA and MMP-9 in group A were significantly decreased (P <0.05) (P <0.05), and was lower than that of group A (P <0.05). The incidence of total cardiovascular events in group B was lower than that of group A (P <0.05). No significant adverse reactions were found in both groups. Conclusion: Early intensive statin treatment can reduce the level of inflammatory cytokines, reduce cardiovascular events, with good efficacy and safety.